Missing results
Finished trials with no published result. When results are never reported, the people who took part are not answered and the record of what works is skewed.
105 of 690 finished trials have no results that we could find, a total of 8,165 participants.
By phase
Phase 2
19%
Phase 3
11%
Phase 4
16%
By time since the trial ended
1 to 2 years ago
21%
2 to 5 years ago
17%
More than 5 years ago
15%
The largest of them
| Trial | Phase | Status | Participants | Ended |
|---|---|---|---|---|
| MAESTRO-02 | Phase 2, Phase 3 | Terminated | 546 | Sept 2009 |
| MAESTRO-03 | Phase 3 | Terminated | 510 | Jul 2009 |
| Interferon beta, phase 3 | Phase 2, Phase 3 | Completed | 399 | Nov 2018 |
| Trial, phase 3 | Phase 3 | Completed | 397 | Mar 2021 |
| Trial, phase 3 | Phase 3 | Terminated | 301 | Jul 2023 |
| Trial, phase 2 | Phase 2 | Completed | 271 | Jul 2020 |
| NOR-MS | Phase 3 | Completed | 267 | Aug 2024 |
| Arbaclofen placarbil, phase 3 | Phase 3 | Completed | 228 | Feb 2013 |
| Int131, phase 2 | Phase 2 | Completed | 228 | Dec 2016 |
| MINDSET01 | Phase 2, Phase 3 | Completed | 218 | Sept 2009 |
| EREVA | Phase 4 | Completed | 196 | Feb 2022 |
| ENLIGHTEN | Phase 3 | Terminated | 188 | May 2025 |
| Abili-T | Phase 2 | Completed | 183 | Oct 2016 |
| VISTA | Phase 2 | Completed | 182 | Jul 2025 |
| MATRIX | Phase 4 | Completed | 180 | Oct 2011 |
| Trial, phase 2 | Phase 2 | Terminated | 173 | Dec 2011 |
| Arbaclofen, phase 3 | Phase 3 | Completed | 150 | Dec 2014 |
| Trial, phase 2 | Phase 2 | Completed | 150 | Mar 2008 |
| Spasticity, phase 2 | Phase 2 | Terminated | 150 | Sept 2008 |
| Amifampridine, phase 3 | Phase 3 | Completed | 126 | Jun 2008 |
| SAFE | Phase 4 | Completed | 121 | May 2022 |
| Methylprednisolone hemisuccinate, phase 2 | Phase 2 | Completed | 102 | Dec 2023 |
| MOTION - JAPAN | Phase 3 | Completed | 101 | Oct 2015 |
| Natalizumab, phase 4 | Phase 4 | Completed | 100 | Dec 2013 |
| Procedure other, phase 2 | Phase 1, Phase 2 | Completed | 100 | Oct 2010 |
Assembled by software from public sources.